Jim Cramer highlights biotech as the top-performing sector, citing regulatory tailwinds and a surge in dealmaking activity.
Jim Cramer has identified biotechnology as the hottest sector in the market, marking a shift from semiconductors and artificial intelligence. The call follows a period of underperformance for biotech, which has recently outpaced broader market gains.
Cramer’s argument centers on a more favorable regulatory environment, particularly at the FDA, which he believes will accelerate mergers and acquisitions. The $27.8 billion Amgen-Horizon Therapeutics deal, which faced antitrust scrutiny, serves as a precedent for future transactions. A backlog of potential targets is now seen as ripe for acquisition.
The sector’s resurgence is driven by expectations of increased deal flow, drawing interest from cash-rich pharmaceutical companies. Investors are weighing whether the momentum justifies reallocating capital toward biotech stocks.